



## DermTech Management to Present at Upcoming Investor Conferences

February 24, 2022

LA JOLLA, Calif.--(BUSINESS WIRE)--Feb. 24, 2022-- DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management will present at the following upcoming conferences:

- Cowen 42nd Annual Health Care Conference  
Presenting on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Time
- Oppenheimer 32nd Annual Healthcare Conference  
Presenting on Tuesday, March 15, 2022 at 3:20 p.m. Eastern Time

Interested parties may access the live webcasts of the presentations and, for 90 days following the Cowen and Oppenheimer conferences, the archived webcasts of the presentations through the "Investor Relations" section of DermTech's website at: [www.DermTech.com](http://www.DermTech.com).

### About DermTech:

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech's investor relations site at: [www.dermtech.com](http://www.dermtech.com).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20220224005265/en/>

DermTech  
Sarah Dion  
[sdion@dermtech.com](mailto:sdion@dermtech.com)  
858.450.4222

ICR Westwicke IR  
Caroline Corner, PhD  
[caroline.corner@westwicke.com](mailto:caroline.corner@westwicke.com)  
415.202.5678

Source: DermTech, Inc.